A
Alexander Rialdi
Researcher at Icahn School of Medicine at Mount Sinai
Publications - 15
Citations - 1079
Alexander Rialdi is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Medicine & Gene. The author has an hindex of 9, co-authored 10 publications receiving 675 citations.
Papers
More filters
Journal ArticleDOI
Transcription Elongation Can Affect Genome 3D Structure.
Sven Heinz,Lorane Texari,Michael G.B. Hayes,Matthew Urbanowski,Max W. Chang,Ninvita Givarkes,Alexander Rialdi,Kris M. White,Randy A. Albrecht,Lars Pache,Ivan Marazzi,Adolfo García-Sastre,Megan L. Shaw,Christopher Benner +13 more
TL;DR: The data indicate that transcription elongation by RNA polymerase II remodels genome 3D architecture and affects cohesin-mediated chromatin contacts within gene bodies.
Journal ArticleDOI
Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation.
Jia Yi Fong,Jia Yi Fong,Luca Pignata,Luca Pignata,Pierre-Alexis Goy,Pierre-Alexis Goy,Kimihito Cojin Kawabata,Stanley Chun-Wei Lee,Cheryl M. Koh,Daniele Musiani,Enrico Massignani,Andriana G. Kotini,Alex Penson,Cheng Mun Wun,Yudao Shen,Megan C. Schwarz,Diana Hp. Low,Alexander Rialdi,Michelle Ki,Heike Wollmann,Slim Mzoughi,Christine Thompson,Timothy K. Hart,Olena Barbash,Genna M. Luciani,Magdalena M. Szewczyk,Bas J. Wouters,Bas J. Wouters,Ruud Delwel,Eirini P. Papapetrou,Dalia Barsyte-Lovejoy,Cheryl H. Arrowsmith,Cheryl H. Arrowsmith,Mark D. Minden,Jian Jin,Ari Melnick,Tiziana Bonaldi,Omar Abdel-Wahab,Ernesto Guccione +38 more
TL;DR: It is identified that inhibiting symmetric or asymmetric dimethylation of arginine, mediated by PRMT5 and type I proteinArginine methyltransferases (PRMTs), respectively, reduces splicing fidelity and results in preferential killing of SF-mutant leukemias over wild-type counterparts.
Journal ArticleDOI
Global Methylation in the Placenta and Umbilical Cord Blood From Pregnancies With Maternal Gestational Diabetes, Preeclampsia, and Obesity
Yoko Nomura,Luca Lambertini,Luca Lambertini,Alexander Rialdi,Men-Jean Lee,Elana Mystal,Elana Mystal,Mordy Grabie,Mordy Grabie,Isaac Manaster,Nancy Huynh,Nancy Huynh,Jackie Finik,Jackie Finik,Mia Davey,Kei Davey,Jenny Ly,Jenny Ly,Joanne Stone,Holly Loudon,Gary S. Eglinton,Yasmin L. Hurd,Yasmin L. Hurd,Jeffrey H. Newcorn,Jia Chen +24 more
TL;DR: It is possible that the placenta tissue, but not umbilical cord blood, may be epigenetically programmed by maternal GDM, preeclampsia, and obesity to carry out its own specific functions that influence fetal growth.
Journal ArticleDOI
Inhibiting Inflammation with Myeloid Cell-Specific Nanobiologics Promotes Organ Transplant Acceptance
Mounia S. Braza,Mandy M. T. van Leent,Marnix Lameijer,Brenda L. Sanchez-Gaytan,Rob J.W. Arts,Carlos Pérez-Medina,Patricia Conde,García M,Maria Gonzalez-Perez,Manisha Brahmachary,Francois Fay,Ewelina Kluza,Susanne Kossatz,Regine J. Dress,Fadi Salem,Alexander Rialdi,Thomas Reiner,Thomas Reiner,Peter Boros,Gustav J. Strijkers,Gustav J. Strijkers,Claudia Calcagno,Florent Ginhoux,Ivan Marazzi,Esther Lutgens,Esther Lutgens,Gerry A. F. Nicolaes,Christian Weber,Filip K. Swirski,Matthias Nahrendorf,Edward A. Fisher,Raphaël Duivenvoorden,Zahi A. Fayad,Mihai G. Netea,Mihai G. Netea,Willem J. M. Mulder,Jordi Ochando,Jordi Ochando +37 more
TL;DR: It is demonstrated that local macrophage activation through dectin‐1 and toll‐like receptor 4 (TLR4) drives trained immunity‐associated cytokine production during allograft rejection and it is shown that HDL‐based nanoimmunotherapy can be employed to control Macrophage function in vivo.
Journal ArticleDOI
Discovery of a first-in-class EZH2 selective degrader.
Anqi Ma,Elias E. Stratikopoulos,Kwang-Su Park,Jieli Wei,Tiphaine Martin,Xiaobao Yang,Megan C. Schwarz,Violetta V. Leshchenko,Alexander Rialdi,Brandon Dale,Alessandro Laganà,Ernesto Guccione,Samir Parekh,Ramon Parsons,Jian Jin +14 more
TL;DR: MS1943 has a profound cytotoxic effect in multiple TNBC cells, while sparing normal cells, and is efficacious in vivo, suggesting that pharmacologic degradation of EZH2 can be advantageous for treating the cancers that are dependent on EZh2.